Defunct Company
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
16
NCT05496686
Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma
Phase: Phase 1
Role: Lead Sponsor
Start: Jul 21, 2022
Completion: Feb 25, 2029